WATERTOWN, Mass.--(BUSINESS WIRE)--Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost the intelligence of the natural immune response to disease, today announced three presentations of data on its dendritic cell hyperactivation (hDC) platform at the 4th Inflammasome Therapeutics Summit, taking place November 29 to December 1, 2022 in Boston, Massachusetts.
Corner has developed proprietary chemical mimics called DC hyperactivators, which stimulate durable protective immunity through the production of polyclonal populations of long-lived memory T cells. DC hyperactivators operate by stimulating inflammasome activities within living dendritic cells, which function to orchestrate T cell immunity. Corner’s technology is particularly effective at inducing protective immunity in elderly or immunocompromised populations, where immune system dysfunction raises the risk of infection and cancer.
Preclinical data in human and mouse model systems demonstrate the ability of Corner Therapeutics’ DC hyperactivators to stimulate inflammasomes in dendritic cells that have migrated to lymph nodes, where the activation of tumor- or infection-specific T cells occurs.
Presentation Overview |
|
Title: |
A Unique Dendritic Cell Activation State Utilizes Inflammasomes to Stimulate Anti-tumor Immunity in Mice |
Presenter: |
Kelsey Finn, PhD |
Dates/Times: |
Wednesday, November 30, 1:00 pm - 2:00 pm |
|
Thursday, December 1, 10:30 am - 11:30 am |
Location: |
Hilton Boston Logan Airport, Boston, MA |
Presentation Overview |
|
Title: |
A Unique Dendritic Cell Activation State Utilizes Inflammasomes to Stimulate Memory T Cell Responses in Humans |
Presenter: |
Emily Gosselin, PhD |
Dates/Times: |
Wednesday, November 30, 1:00 pm - 2:00 pm |
|
Thursday, December 1, 10:30 am - 11:30 am |
Location: |
Hilton Boston Logan Airport, Boston, MA |
Corner’s scientific cofounder and Advisor, Jonathan Kagan, PhD, will present a seminar on the control of anti-tumor immunity in elderly populations, exploring potential cancer biomarkers and their relation to inflammasome activity, and how this knowledge can be translated into therapeutic regimens for patients.
Presentation Overview |
|
Title: |
Inflammasomes and the Control of Anti-Tumor Immunity |
Presenter: |
Jonathan Kagan, PhD |
Date/Time: |
Thursday, December 1, 2022, 3:30 pm |
Location: |
Hilton Boston Logan Airport, Boston, MA |
“The data we’re sharing at the Inflammasome Therapeutics summit showcases our ability to stimulate and hyperactivate DCs through inflammasome activity, to drive robust and long-lasting T cell memory,” said Steven M. Altschuler, MD, CEO and Board Chair of Corner. “While many approaches focus on suppressing the inflammasome, Corner’s technology represents a true paradigm shift in immunotherapy.”
About Corner Therapeutics, Inc.
Corner Therapeutics is a privately held biotech company developing a new class of multi-purpose dendritic cell-targeting immunotherapies that induce robust memory T cell responses. Corner Therapeutics is exploiting a new scientific paradigm to boost the intelligence of the natural immune response through dendritic cell hyperactivation. Our unique approach engages dendritic cell inflammasomes to induce exceptional memory T cell responses critical for lifelong immunity. Our platform is antigen-agnostic and aims to address an exceptionally wide range of difficult-to-treat cancers and infectious diseases. Corner's therapy will usher in a new era of rapid, patient-friendly and low-cost treatments able to induce complete and durable protective immunity. Our foundational science originated from the Kagan and Karp labs at the Harvard Medical School and is being advanced by pioneers of immunotherapy. For more information, please visit https://cornertx.com.
